Mithrl has announced a $20 million Series A, led by Obvious Ventures, with participation from Headline, AGI House, and several pharmaceutical executives. The announcement brings up an increasingly important challenge in...read more
Category - Announcements
Tempus Acquires Personalis and Raises the Stakes in the MRD Market
The acquisition combines Personalis’s highly sensitive molecular residual disease (MRD) technology with Tempus’s commercial reach, multimodal data, and AI-enabled precision-oncology platform. TL;DR: Tempus AI’s proposed...read more
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus’ reach across the...read more
Abbott to acquire Exact Sciences
• Acquisition adds a new growth vertical to Abbott’s already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments•...read more
